Welcome to our dedicated page for Allogene Therapeutics SEC filings (Ticker: ALLO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SEC documents for a clinical-stage biotech are rarely light reading. Allogene Therapeutics’ 10-K blends immunology, CRISPR engineering, and complex revenue-recognition rules, while Form 4s can spike around trial milestones. If you have ever searched for “Allogene Therapeutics insider trading Form 4 transactions” or wondered how to extract cash-burn insights from a dense quarterly report, you know the challenge.
Stock Titan solves that problem. Our platform delivers AI-powered summaries that turn ALLO’s disclosures into plain English. Open the “Allogene Therapeutics quarterly earnings report 10-Q filing” and our engine flags R&D spend, enrollment updates, and liquidity runway in seconds. Need real-time alerts? We stream “Allogene Therapeutics Form 4 insider transactions real-time” so you can see executive stock moves the moment they hit EDGAR. Whether you are “understanding Allogene Therapeutics SEC documents with AI” for pipeline analysis or seeking an “Allogene Therapeutics earnings report filing analysis” to gauge dilution risk, every key point is surfaced automatically.
Our coverage spans every form: an “Allogene Therapeutics annual report 10-K simplified” to spotlight Dagger® manufacturing scale; an “Allogene Therapeutics proxy statement executive compensation” to reveal incentives linked to Phase 2 data; even an “Allogene Therapeutics 8-K material events explained” when the company announces FDA feedback or secondary offerings. Professional investors use these insights to monitor “Allogene Therapeutics executive stock transactions Form 4,” compare trial costs across quarters, and track strategic collaborations with ease. No more hunting through hundreds of pages—our AI delivers what matters, right when you need it.
Insider Trading Alert: Allogene Therapeutics (ALLO) Director Vicki L. Sato received a significant stock option grant on June 18, 2025. The transaction details reveal:
- Granted 144,400 stock options to purchase common stock
- Exercise price set at $1.29 per share
- Options expire on June 18, 2035
- Vesting schedule: Equal monthly installments over 12 months
This Form 4 filing indicates a standard director compensation package through equity incentives. The relatively low exercise price and extended 10-year expiration term suggest a long-term alignment with shareholder interests. The monthly vesting schedule encourages continued service on the board. The transaction was executed directly, with no indirect ownership reported.
Allogene Therapeutics (ALLO) director Deborah M. Messemer received a significant equity grant on June 18, 2025. The insider was awarded 95,400 Restricted Stock Units (RSUs) with the following key terms:
- RSUs will vest in two equal semi-annual installments over one year from grant date
- Each RSU represents a right to receive one share of common stock
- Grant price was $0, as typical for RSU awards
- Director elected to defer receipt of shares until either:
- 30 days after Board separation
- Company change in control
This Form 4 filing represents standard non-employee director compensation and demonstrates continued alignment between board member and shareholder interests through equity-based compensation.
Franz B. Humer, Director at Allogene Therapeutics (ALLO), received a grant of 95,400 Restricted Stock Units (RSUs) on June 18, 2025. The RSUs represent the right to receive an equivalent number of common stock shares.
Key terms of the RSU grant:
- Vesting Schedule: Equal semi-annual installments over one year from grant date
- Exercise Price: $0
- Special Deferral: Humer elected to defer receipt of shares until either:
- 30 days after Board separation, or
- Company change in control
This Form 4 filing was submitted by Earl Douglas (Attorney-in-fact) on June 20, 2025, reporting the transaction under Section 16(a) of the Securities Exchange Act. The grant appears to be part of the company's Non-Employee Director Compensation Policy.
Elizabeth A. Barrett, Director of Allogene Therapeutics (ALLO), received a significant equity grant on June 18, 2025. The transaction involved the acquisition of 95,400 Restricted Stock Units (RSUs) with a $0 exercise price.
Key terms of the RSU grant:
- Vesting occurs in two equal semi-annual installments over one year from grant date
- Each RSU converts to one share of common stock
- Barrett elected to defer receipt of shares until either:
- 30 days after Board separation
- Company change in control
The grant represents part of the company's Non-Employee Director Compensation Policy. The filing was executed by Earl Douglas as Attorney-in-Fact on June 20, 2025.
Allogene Therapeutics (ALLO) director Stephen Mayo received a significant equity grant on June 18, 2025, consisting of 95,400 Restricted Stock Units (RSUs). The RSUs will vest in two equal semi-annual installments over a one-year period from the grant date.
Key terms of the RSU grant:
- Each RSU represents one share of common stock
- Grant price: $0
- Mayo elected to defer receipt of shares until either:
- 30 days after Board separation
- Company change in control
This Form 4 filing, executed by Earl Douglas as attorney-in-fact on June 20, 2025, reflects standard non-employee director compensation practices. The grant strengthens Mayo's alignment with shareholder interests through increased equity ownership.
Director Joshua A. Kazam of Allogene Therapeutics (ALLO) received a grant of 94,500 Restricted Stock Units (RSUs) on June 18, 2025. This represents a significant equity compensation award for the board member.
Key details of the RSU grant:
- Each RSU converts to one share of common stock
- Vesting occurs in two equal semi-annual installments over one year from grant date
- Exercise price is $0
- Vesting is contingent on continued service as director
The filing was reported via Form 4 on June 20, 2025, within the required two-business-day window for insider transaction reporting. The transaction represents a direct ownership position and was executed pursuant to the company's director compensation program.
Allogene Therapeutics (Nasdaq: ALLO) filed a Form 8-K reporting the voting results of its 2025 Annual Meeting of Stockholders held on June 18, 2025.
- Director elections: Stockholders re-elected Elizabeth Barrett (131,435,760 FOR), Arie Belldegrun M.D. (150,891,245 FOR) and David Chang M.D. Ph.D. (153,721,017 FOR) as Class I directors, each to serve until the 2028 annual meeting. Broker non-votes totaled 33,512,034 shares.
- Executive compensation: The non-binding advisory vote approved the compensation of named executive officers with 139,947,868 FOR versus 14,233,309 AGAINST and 3,184,237 abstentions.
- Auditor ratification: Ernst & Young LLP was confirmed as independent registered public accounting firm for fiscal 2025 with 190,111,256 FOR and only 414,604 AGAINST.
No other items were presented. The filing contains no updates on financial performance, strategic initiatives, or legal matters.
FAQ
What is the current stock price of Allogene Therapeutics (ALLO)?
What is the market cap of Allogene Therapeutics (ALLO)?
What is Allogene Therapeutics’ primary focus?
How does the allogeneic approach differ from autologous therapies?
What technologies underpin Allogene’s product development?
How does Allogene generate revenue in its current stage?
Which indications are targeted by Allogene’s pipeline?
What role do minimal residual disease (MRD) assays play in their programs?
Who are the key stakeholders in Allogene Therapeutics’ management team?
How is the company positioned within the competitive landscape?
